Enterprise Value
-43.72M
Cash
91.35M
Avg Qtr Burn
-15.72M
Short % of Float
8.47%
Insider Ownership
3.47%
Institutional Own.
64.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BDC-3042 Details Solid tumor/s, Cancer | Phase 1/2 Update | |
BDC-1001 +/- pertuzumab Details HER2-expressing cancers | Failed Discontinued |